EGFR mutations, including L858R and T790M, are common in NSCLC. TKIs like erlotinib and gefitinib target these mutations but lose effectiveness within a year due to secondary mutations.
LAS VEGAS , March 11, 2025 /PRNewswire/ -- DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback